ICCM — Icecure Medical Share Price
Last trade - 00:00- $54.42m
- $43.36m
- $3.23m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.47 | ||
| Price to Tang. Book | 4.47 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 16.85 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -124.22% | ||
| Return on Equity | -77.97% | ||
| Operating Margin | -482.38% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 1.61 | 3.87 | 4.14 | 3.08 | 3.23 | 4.14 | 6.8 | 23.5% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Icecure Medical Ltd is an Israel-based company that is engaged in the healthcare sector. The Company operates as commercial stage medical device company focusing on the research, development and marketing of cryoablation systems, disposables and technologies based on liquid nitrogen, or LN2, for treating tumors. Cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in breast, lungs, kidneys, bones and other indications. Company's lead product is ProSense system, a single probe system, but in addition the Company developed an additional multi probe system that is expected to have the ability to freeze several tumors simultaneously or larger tumors, named MultiSense system, which has not yet been commercialized.
Directors
- Ron Mayron CHM (58)
- Eyal Shamir CEO (57)
- Ronen Tsimerman VFN (48)
- Elisabeth Sadka VPR (49)
- Naum Muchnik VRD (42)
- Tlalit Bussi Tel-Tzure VBD (47)
- Yaacov Goldman NED (64)
- Sharon Levita NED (51)
- Oded Tamir NED (64)
- Doron Birger IND (70)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- January 25th, 2006
- Public Since
- February 2nd, 2011
- No. of Shareholders
- 4
- No. of Employees
- 71
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 45,729,684
- Address
- 7 Ha'eshel St.,, CAESAREA, 3079504
- Web
- https://icecure-medical.com/
- Phone
- +972 46230333
- Auditors
- Brightman Almagor Zohar & Co
Upcoming Events for ICCM
Similar to ICCM
Accelerate Diagnostics
NASDAQ Capital Market
Acutus Medical
NASDAQ Capital Market
Adapthealth
NASDAQ Capital Market
Aethlon Medical
NASDAQ Capital Market
Agape ATP
NASDAQ Capital Market
FAQ
As of Today at 19:11 UTC, shares in Icecure Medical are trading at $1.19. This share price information is delayed by 15 minutes.
Shares in Icecure Medical last closed at $1.19 and the price had moved by +3.48% over the past 365 days. In terms of relative price strength the Icecure Medical share price has underperformed the S&P500 Index by -16.53% over the past year.
The overall consensus recommendation for Icecure Medical is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Icecure Medical does not currently pay a dividend.
Icecure Medical does not currently pay a dividend.
Icecure Medical does not currently pay a dividend.
To buy shares in Icecure Medical you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $1.19, shares in Icecure Medical had a market capitalisation of $54.42m.
Here are the trading details for Icecure Medical:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: ICCM
Based on an overall assessment of its quality, value and momentum Icecure Medical is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Icecure Medical is $3.33. That is 179.83% above the last closing price of $1.19.
Analysts covering Icecure Medical currently have a consensus Earnings Per Share (EPS) forecast of -$0.29 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Icecure Medical. Over the past six months, its share price has outperformed the S&P500 Index by +33.3%.
As of the last closing price of $1.19, shares in Icecure Medical were trading +9.43% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Icecure Medical PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.19.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Icecure Medical's management team is headed by:
- Ron Mayron - CHM
- Eyal Shamir - CEO
- Ronen Tsimerman - VFN
- Elisabeth Sadka - VPR
- Naum Muchnik - VRD
- Tlalit Bussi Tel-Tzure - VBD
- Yaacov Goldman - NED
- Sharon Levita - NED
- Oded Tamir - NED
- Doron Birger - IND